

# November 2025 Content Release Notes

November 20, 2025

## Contents

Clinical Profile Documentation .....	2
Updates .....	2
Problem Groups .....	2
Updates .....	2
Lab Analytes & Panels .....	2
Additions .....	2
Medications .....	3
Additions .....	3
Updates .....	4
Regimen Library .....	5
Additions .....	5
Updates .....	7
Billing & HCPCS Codes .....	8
Updates .....	8

## Clinical Profile Documentation

### Updates

Users will see updated values and descriptions for **Primary Tumor Type (T)**, **Regional Lymph Nodes (N)**, and **Distance Metastasis (M)**, documentation points for **Nasopharyngeal cancer**.

## Problem Groups

### Updates

ALK rearrangement status has been updated to **ALK fusion status** for **Lung Cancer, Non-small Cell (NSCLC)**, **Lymphoma, Non-Hodgkins (NHL) (Parent)**, and **Uterine Cancer, Sarcoma**. **EGFR status** has been updated for **Lung Cancer, Non-small Cell (NSCLC)** with the following:

- Exon 19 deletion or Exon 21 L858R is now **Exon 19 deletion or L858R**

## Lab Analytes & Panels

### Additions

- 5-Hydroxyindoleacetic acid (5-HIAA), 24-hour urine without creatinine panel
- 5-Hydroxyindoleacetic acid (5-HIAA), 24-hour urine, with creatinine panel
- ADAMTS13 activity panel
- Biotin (Vitamin B7) panel
- BKV DNA log10, urine, IU/mL
- Calcium pyrophosphate, synovial fluid
- CSF PCR Panel
- CSF PCR results
- Cytogenetics PDF
- DNA double stranded Ab, IgG, S
- DPYD Genotype DYPD interpretation
- DPYD phenotype activity score
- Fibrin clot, synovial fluid
- Glutathione, Total Panel
- Guardant report
- Guardant360 tissue IHC panel
- Invitae BRCA2 panel
- Invitae DICER1 panel
- Invitae PALB2 panel

- Invitae protein S deficiency panel
- Invitae STAT3 panel
- Lining/Macro, Synovial fluid
- Monocytes, synovial fluid
- Neo Comprehensive heme cancers DNA+RNA panel (NeoGenomics)
- NeoGenomics bone marrow failure NGS panel
- NeoTYPE CLL profile panel
- Neutrophils, synovial fluid
- PTH, Intact without Calcium panel
- SiParadigm report
- Synovial Fluid Analysis Panel
- Tempus Summary Report
- Tempus Summary Report Panel
- Tempus xG (common hereditary cancers) 52 gene amendment panel
- THSD7A Ab, S
- THSD7A Ab, S panel
- Urates, synovial fluid
- Urine protein, total, random without creatinine panel

## Medications

### Additions

- BBO-8520 invest Oral
- B Complex (Compound) (Olympia Vita-Complex (Compound) IM)
- Diazepam Suppository
- KB707 invest Inhalation
- Lipo-Mino-Mix-C (compound) IM
- LipoSlim (compound) (Lipo-Mino-Mix-C (compound) IM)
- MICC (compound) IM
- Myers' Cocktail (compound) IV
- Nifedipine Compound Topical
- Olympia Vita-Complex (Compound) IM
- Recovery & Performance (compound) IV
- RO7840734 (GDC-4198) invest Oral
- Vitamin D 50,000 IU (compound) IM

## Updates

Medications	Updates
<b>Campath (Alemtuzumab IV)</b>	Now Active and Orderable. Please note: This medication term will not trigger interaction alerts or provide patient education materials.
<b>Methylcobalamin IV</b>	Updated Dose Form to: <ul style="list-style-type: none"> <li>• 5 mg/mL solution</li> </ul>
<b>PEG-Electrolyte Oral Liquid</b>	New Quick SIG Pick available: <ul style="list-style-type: none"> <li>• 240 mL orally As Directed; Gavilyte 4 L bottle. QTY 4 L or 4,000 mL. At 4pm Drink 8 oz every 10 to 15 mins until half of the bottle is gone. 4 hrs before procedure drink the remaining solution every 10 to 15 mins until gone</li> </ul>
<b>T-Dxd invest (DS-8201a invest IV)</b>	Updated Name to: <ul style="list-style-type: none"> <li>• T-DXd invest (DS-8201a invest IV)</li> </ul> Removed SIGs: <ul style="list-style-type: none"> <li>• 0 mg/m<sup>2</sup> intravenously once</li> </ul>
<b>Taletrectinib (AB-106/DS-6051b invest Oral)</b>	Updated Dose Form to: <ul style="list-style-type: none"> <li>• 100 mg capsule (also for Research)</li> </ul>
<b>TOS-358 invest Oral</b>	Inactive Forms: <ul style="list-style-type: none"> <li>• 1 mg capsule</li> <li>• 5 mg capsule</li> <li>• 25 mg capsule</li> </ul> New Forms available: <ul style="list-style-type: none"> <li>• 1 mg tablet</li> <li>• 5 mg tablet</li> </ul>
<b>Venetoclax Oral Starter Pack 10 mg-50 mg-100 mg</b>	New Quick SIG Pick available: <ul style="list-style-type: none"> <li>• 1 package orally As Directed</li> </ul>

# Regimen Library

## Additions

Regimen Name	Diagnosis
ABVD (1 cycle) Q28D	Lymphoma, Hodgkin (HL)
Acalabrutinib + Obinutuzumab + Venetoclax Q28D (MRD-Guided Discontinuation)	Leukemia, Chronic Lymphocytic (CLL)
ALL E1910 Consolidation Q28D (Part 5 of 10)	Leukemia, Acute Lymphocytic (ALL)
ALL E1910 Consolidation Q28D (Part 8 of 10)	Leukemia, Acute Lymphocytic (ALL)
ALL E1910 Consolidation Q42D (Blinatumomab, 7-day bag change) (Parts 4,7,9 of 10)	Leukemia, Acute Lymphocytic (ALL)
ALL E1910 Consolidation Q42D (Part 6 of 10)	Leukemia, Acute Lymphocytic (ALL)
ALL E1910 Induction Cycle 1 Q28D (Part 1 of 10)	Leukemia, Acute Lymphocytic (ALL)
ALL E1910 Induction Cycle 2 Q42D (Part 2 of 10)	Leukemia, Acute Lymphocytic (ALL)
ALL E1910 Intensification Q28D (Part 3 of 10)	Leukemia, Acute Lymphocytic (ALL)
ALL E1910 Maintenance Q84D (Part 10 of 10)	Leukemia, Acute Lymphocytic (ALL)
Atezolizumab IV + Lurbinectedin Q21D	Lung Cancer, Small Cell (SCLC)
Atezolizumab SQ + Lurbinectedin Q21D	Lung Cancer, Small Cell (SCLC)
Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Pembrolizumab SQ Q21D	Esophageal Cancer (Parent); Gastric Cancer
Capecitabine D1-28 + Cisplatin D1,15 + Abraxane D1,15 + Gemcitabine D1,15 Q28D	Pancreatic Cancer
Enfortumab vedotin-ejfv D1,8,22,29 + Pembrolizumab SQ Q42D	Bladder Cancer, Renal Pelvis and Ureter Cancer, Urethral Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Trastuzumab IV Q14D + Pembrolizumab SQ Q42D	Esophageal Cancer (Parent); Gastric Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) (Q14D) + Trastuzumab IV + Pembrolizumab SQ (Q21D) Q42D	Esophageal Cancer (Parent); Gastric Cancer
Gemcitabine Intravesical Implant (Inlexzo) Q21D	Bladder Cancer, Renal Pelvis and Ureter Cancer, Urethral Cancer
GFR Dermatologic Prophylaxis Q28D	All Problems

Regimen Name	Diagnosis
Ibrutinib (2 cycles) fb Ibrutinib + Venetoclax Q28D (MRD-Guided Discontinuation)	Leukemia, Chronic Lymphocytic (CLL)
Imlunestrant + Goserelin Q28D	Breast Cancer
Imlunestrant + Leuprolide Q28D	Breast Cancer
Imlunestrant Q28D	Breast Cancer
Nivolumab (3 mg/kg) + Ipilimumab (1 mg/kg) C1 D1,22,43,64 (Q21D) fb Nivolumab SQ C2+ D1,29,57 (Q28D) Maintenance Q84D	Colon Cancer, Melanoma, Skin, Neuroendocrine Tumor, Carcinoid (Parent), Pancreatic Cancer, Carcinoid/Neuroendocrine, Rectal Cancer, Renal Cell Carcinoma (RCC)
Pembrolizumab SQ + Abraxane D1,8,15 + Carboplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab SQ + Axitinib Q42D	Renal Cell Carcinoma (RCC)
Pembrolizumab SQ + Bevacizumab Q21D Maintenance (Cervical)	Cervical Cancer
Pembrolizumab SQ + Bevacizumab + Cyclophosphamide PO Q21D	Ovarian and Primary Peritoneal Cancer; Fallopian Tube Cancer;
Pembrolizumab SQ + Docetaxel + Carboplatin Q21D (Neoadjuvant Breast)	Breast Cancer
Pembrolizumab SQ + Lenvatinib Q42D	Melanoma, Skin, Renal Cell Carcinoma (RCC), Uterine Cancer (Parent)
Pembrolizumab SQ (Q21D) + Abraxane (D1,8,15 Q28D) Q84D	Breast Cancer
Pembrolizumab SQ + Docetaxel + Carboplatin Q21D (Part 1 of 2)	Head and Neck Cancer (Parent)
Pembrolizumab SQ + Gemcitabine D1,8 + Carboplatin D1,8 Q21D	Breast Cancer
Pembrolizumab SQ + Gemcitabine D1,8 + Cisplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab SQ (Q21D) + Paclitaxel (D1,8,15 Q28D) Q84D	Breast Cancer
Pembrolizumab SQ + Paclitaxel D1,8,15,22,29,36 + Carboplatin D1,8,15,22,29,36 Q42D fb Pembrolizumab SQ + Doxorubicin + Cyclophosphamide (AC) D1,22 Q42D	Breast Cancer
Pembrolizumab SQ + Pemetrexed + Cisplatin Q21D	Lung Cancer, Small Cell (SCLC)
Pembrolizumab SQ + Pemetrexed Maintenance Q42D	Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab SQ Q21D (Part 2 of 2: Head and Neck Cancer Maintenance)	Head and Neck Cancer (Parent)
Pembrolizumab SQ Q42D (Adjuvant Breast)	Breast Cancer

Regimen Name	Diagnosis
<b>Pembrolizumab SQ Q42D (Cervical Maintenance)</b>	Cervical Cancer
<b>Tislelizumab-jsgr + Gemcitabine + Oxaliplatin (GemOx) Q21D (Part 1 of 2: Induction)</b>	Lymphoma, Hodgkin (HL)
<b>Tislelizumab-jsgr + Gemcitabine + Oxaliplatin (GemOx) Q21D (Part 2 of 2: Tislelizumab-jsgr Q56D Maintenance)</b>	Lymphoma, Hodgkin (HL)
<b>Zanubrutinib (3 cycles) fb Zanubrutinib + Venetoclax Q28D (MRD-Guided Discontinuation)</b>	Leukemia, Chronic Lymphocytic (CLL)

## Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Bile Duct Cancer (Parent)
- Bladder Cancer
- Brain Tumor (Parent)
- Breast Cancer
- Colon Cancer
- Fallopian Tube Cancer
- Gallbladder Cancer
- Head and Neck Cancer (Parent)
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Hodgkin (HL),
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Malignant Pleural Mesothelioma
- Melanoma, Skin
- Ovarian and Primary Peritoneal Cancer
- Rectal Cancer
- Renal Pelvis and Ureter Cancer
- Thymoma, Malignant
- Urethral Cancer
- Uterine Cancer (Parent)

# Billing & HCPCS Codes

## Updates

Medication	HCPCS Codes
Belantamab Mafodotin-blmf	J9999 per 200 mg
Piperacillin-Tazobactam (8:1) IV	J3490 per 3.375 g
Ustekinumab-hmny IV	J3590 per 260 mg
Ustekinumab-hmny Subcutaneous	J3590 per 45 mg